NASDAQ: INMDInmode Ltd Stock
$17.36-0.01 (-0.06%)
Updated Apr 24, 2024
INMD Price
$17.36
Fair Value Price
$32.78
Market Cap
$1.46B
52 Week Low
$16.96
52 Week High
$48.25
P/E
7.32x
P/B
1.85x
P/S
3.78x
PEG
0.24x
Dividend Yield
N/A
Revenue
$492.05M
Earnings
$197.92M
Gross Margin
83.6%
Operating Margin
44.16%
Profit Margin
40.2%
Debt to Equity
0.1
Operating Cash Flow
$177M
Beta
1.6
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INMD Overview
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INMD ($17.36) is undervalued by 47.04% relative to our estimate of its Fair Value price of $32.78 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INMD ($17.36) is significantly undervalued by 47.04% relative to our estimate of its Fair Value price of $32.78 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INMD ($17.36) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INMD due diligence checks available for Premium users.
Be the first to know about important INMD news, forecast changes, insider trades & much more!
INMD News
Valuation
INMD fair value
Fair Value of INMD stock based on Discounted Cash Flow (DCF)
Price
$17.36
Fair Value
$32.78
Undervalued by
47.04%
INMD ($17.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INMD ($17.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INMD ($17.36) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.32x
Industry
30.46x
Market
41.27x
INMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
INMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.85x
Industry
3.73x
INMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
INMD is good value based... subscribe to Premium to read more.
PEG Value Valuation
INMD's financial health
Profit margin
Revenue
$126.8M
Net Income
$55.2M
Profit Margin
43.5%
INMD's Earnings (EBIT) of $217.27M... subscribe to Premium to read more.
Interest Coverage Financials
INMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$863.3M
Liabilities
$75.9M
Debt to equity
0.1
INMD's short-term assets ($845.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INMD's short-term assets ($845.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$61.2M
Investing
-$51.6M
Financing
$275.0k
INMD's operating cash flow ($176.83M)... subscribe to Premium to read more.
Debt Coverage Financials
INMD vs Medical Device Stocks
Inmode Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.